Patent classifications
C12N2501/01
GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITH POLYCISTRONIC SOX2, KLF4, AND OPTIONALLY C-MYC
Described herein a polycistronic expression cassettes and expression vectors that include a promoter operably linked to a nucleic acid segment that encodes a Sox2 and Klf4 polypeptide. The nucleic acid segment can also encode a c-Myc polypeptide. Expression of such polycistronic expression cassettes/vectors in host cells can reprogram the host cells to stem cells or other types of reprogrammed cells.
Methods of identification and use of nematicide compounds
The invention relates, in part, to methods to identify compounds to treat a phytoparasitic nematode infection and/or reduce phytoparasitic nematode contamination, and to methods and compositions to treat phytoparasitic nematode infections and to reduce phytoparasitic nematode contamination of a substrate such as, but not limited to: a plant, agricultural medium, or soil.
METHODS OF DIFFERENTIATING NEURAL CELLS AND RELATED COMPOSITIONS AND METHODS OF USE
The present disclosure provides methods of lineage specific differentiation of pluripotent stem cells, including induced pluripotent stem cells, into floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and/or DA neurons. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.
Method for Producing Brown Adipocytes
The present invention is primarily directed to provide a new process capable of performing direct conversion of or induction from a somatic cell to brown adipocytes with low molecular weight compounds, without performing artificial gene transfer.
The present invention includes, for example, a process for producing brown adipocytes by direct differentiation induction from somatic cells, comprising a step of culturing a somatic cell in a serum-free differentiation induction medium in the presence of a selective PPARγ agonist and a cAMP inducer.
According to the present invention, direct conversion of or induction from somatic cells to brown adipocytes can be effectively performed without gene transfer. The brown adipocytes obtained by the present invention are useful as regenerative medicine, models of human brown adipocytes and human beige cells, and the like.
Induction of differentiation of induced pluripotent stem cells into intestinal epithelial cells
An object of the present invention is to provide a novel method which enables convenient preparation of cells exhibiting functions close to that of intestinal epithelial cells of living bodies, and use of the method. The differentiation of induced pluripotent stem cells into intestinal epithelial cells is induced by step of differentiating induced pluripotent stem cells into endoderm-like cells; step of differentiating the endoderm-like cells obtained in step into intestinal stem cell-like cells; and step of differentiating the intestinal stem cell-like cells obtained in step into intestinal epithelial cell-like cells, wherein step includes culture in the presence of a MEK1 inhibitor, a DNA methyltransferase inhibitor, a TGF-β receptor inhibitor, and EGF and under the condition that cAMP is supplied to the cells.
PRODUCTION METHOD FOR CEREBRAL ORGANOID
A production method for a cerebral organoid having amyloid plaques is provided, the method including a step (a) of forming, in the presence of a SMAD inhibitor, an embryoid body from a pluripotent stem cell having a mutation in an Alzheimer's disease-related gene; a step (b) of embedding the embryoid body after the step (a) in an extracellular matrix and three-dimensionally culturing the embedded embryoid body in the presence of a SMAD inhibitor and a glycogen synthase kinase 3β (GSK3β) inhibitor to form an organoid; and a step (c) of removing the organoid after the step (b) from the extracellular matrix and subjecting the removed organoid to stirring culture in a medium, where at least a part of the step (c) is carried out in the presence of leukemia inhibitory factor (LIF).
DIRECT REPROGRAMMING OF SOMATIC CELLS INTO MYOGENIC CELLS
Described herein are methods of generating induced muscle progenitor cells (iMPCs) and uses thereof. Embodiments further provide for methods of promoting muscle regeneration and/or repair and methods of treating a muscle disease or disorder.
METHODS OF GENERATING HUMAN ENDOMETRIAL STROMAL FIBROBLASTS AND THREE-DIMENSIONAL MULTI-LAYERED HUMAN ENDOMETRIAL TISSUE COMPOSITIONS
Disclosed herein are methods for obtaining endometrial stromal fibroblast cells from pluripotent stem cells, such as induced pluripotent stem cells. The present disclosure also provides methods of obtaining a three-dimensional, multilayered endometrial tissue composition. Methods of using the cells and tissue compositions in drug screening and therapeutic applications are also provided.
TUMOR-INFILTRATING LYMPHOCYTES WITH ENHANCED TUMOR REACTIVITY
Disclosed are compositions and methods for targeted treatment of infections and cancers expressing cancers. In particular, tumor infiltrating lymphocytes (TILs) are identified that can be used with adoptive cell transfer to target, penetrate, and kill solid tumor masses. Therefore, also disclosed are methods of providing an immunotherapy in a subject with an infection or cancer that involves adoptive transfer of the disclosed TILs.
PHARMACEUTICAL COMPOSITION FOR ALZHEIMER'S TREATMENT CONTAINING AS ACTIVE INGREDIENT LATE PASSAGE HUMAN MESENCHYMAL STEM CELLS INDUCED TO DIFFERENTIATE INTO GLIA-LIKE CELLS
The present invention relates to a pharmaceutical composition for Alzheimer's treatment containing as an active ingredient of late-stage human mesenchymal stem cells induced into glia-like cells (ghMSCs). When the glia-like cells differentiated from the late-stage human mesenchymal stem cells were co-cultured with neural stem cells having toxicity induced by amyloid beta, effects of increasing the reduced viability and proliferative potential of the neural stem cells and reducing the increased cytotoxicity of the neural stem cells were verified. In addition, the expression of inflammasomes is reduced, and effects of improving long-term memory with respect to spatial perception ability and enhancing spatial cognitive ability in Alzheimer-induced mouse models were verified. Therefore, the pharmaceutical composition of the present invention can be advantageously used in Alzheimer's treatment.